What do Cardiovascular Outcome Trials and the Queen Mary have in Common?

By Chris Standley, Vice President of Vendor Governance, Worldwide Clinical Trials,

On January 12, 2004 when Queen Mary 2 set sail on her maiden voyage from Southampton, England, to Fort Lauderdale, Florida, in the United States, carrying 2,620 passengers, she was both the longest (345 meters – equivalent to 36 London double-decker buses) and largest (148,528 gross tonnage) passenger ship ever built. Whilst she no longer holds these distinctions, she remains the largest ocean liner ever constructed.

Read More

New Hypertension Guidelines: What’s Next for Hypertension Therapy?

By Toni Bransford, MD, FACC Executive Medical Director, Scientific Solutions, Cardiovascular and Metabolic Division, Worldwide Clinical Trials and Karen Modesto, MD, Senior Medical Director, Medical and Scientific Affairs, Cardiovascular and Metabolic Division, Worldwide Clinical Trials,

  Heart disease is the No. 1 cause of death in the world and the leading cause of death in the United States, killing about 610,000 people every year–that’s 1 in every 4 deaths, claiming more lives than all forms of cancer combined1, 2. Having high blood pressure puts you at risk for heart disease and stroke, which are leading causes of death. About 75 million American adults (32%) have high blood pressure—that’s 1 in every 3 adults and high blood pressure was a primary or contributing cause of death for more than 410,000 Americans in 2014—that’s more than 1,100 deaths each day1, 3.

Read More

Successfully Mitigating Costs in Large Cardiovascular Outcome Trials

By Karen Hill, Senior Vice President, Project Management, Cardiometabolic, Worldwide Clinical Trials,

  The rising costs of clinical trials are especially pronounced in large cardiovascular outcome trials (CVOTs) due to the number of patients, investigators, clinical sites, and countries involved. However, there have been several successful attempts by Worldwide Clinical Trials, in partnership with sponsors and others, to mitigate these costs in recent years. Following is a summary of a few cost mitigation strategies employed in CVOTs.

Read More

5 Tips for Developing Lifestyle Modification Programs in Cardiovascular Outcome Trials

By Nancy Newark, BSN, RN, Executive Director, Project Management, Cardiometabolic & Late Phase, Worldwide Clinical Trials,

In recent years an increasing number of cardiovascular outcome trials have been completed in patients with diabetes and obesity with high cardiovascular risk. In one of these studies, Worldwide Clinical Trials supported the development of a lifestyle modification program in partnership with the sponsor. Designed to encourage diet and exercise, this program included a survey of study participants to evaluate its impact. The survey results revealed that engagement in the program was lower than anticipated. However, there are several lessons learned that can be applied to similar healthy lifestyle initiatives in cardiovascular outcome trials.

Read More

Go Red: Know Your Numbers

By Toni Bransford, M.D., FACC Executive Medical Director, Scientific Solutions, Cardiovascular and Metabolic Division, Worldwide Clinical Trials and Karen Modesto, MD, Senior Medical Director, Medical and Scientific Affairs, Cardiovascular and Metabolic Division, Worldwide Clinical Trials,

This week begins Heart Month; a special time of year, used to shine a light on women’s risk of heart disease. Go Red Day occurs this Friday, February 2nd; Worldwide Clinical Trials will celebrate Go Red Day February 9th.

Read More